Cyteir Therapeutics CYT Stock
3.02 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGS
Market Cap
108.71M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Cyteir Therapeutics Price Chart
Cyteir Therapeutics CYT Financial and Trading Overview
| Cyteir Therapeutics stock price | 3.02 USD |
| Previous Close | 2.12 USD |
| Open | 2.12 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 2200 |
| Day's Range | 2 - 2.15 USD |
| 52 Week Range | 1.13 - 4.22 USD |
| Volume | 74.61K USD |
| Avg. Volume | 38.12K USD |
| Market Cap | 71.03M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.67 USD |
CYT Valuation Measures
| Enterprise Value | -61944808 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6393442 |
| PEG Ratio (5 yr expected) | -0.04 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.5274261 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.392 |
Trading Information
Cyteir Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -3.38% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.22 USD |
| 52 Week Low | 1.13 USD |
| 50-Day Moving Average | 2.13 USD |
| 200-Day Moving Average | 1.79 USD |
CYT Share Statistics
| Avg. Volume (3 month) | 38.12K USD |
| Avg. Daily Volume (10-Days) | 43.56K USD |
| Shares Outstanding | 35.51M |
| Float | 14.86M |
| Short Ratio | 5.83 |
| % Held by Insiders | 11.90% |
| % Held by Institutions | 75.67% |
| Shares Short | 216.25K |
| Short % of Float | 1.01% |
| Short % of Shares Outstanding | 0.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -17.37% |
| Return on Equity (ttm) | -28.72% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -44502000 USD |
| Net Income Avi to Common (ttm) | -44445000 USD |
| Diluted EPS (ttm) | -1.27 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 137.2M USD |
| Total Cash Per Share (mrq) | 3.87 USD |
| Total Debt (mrq) | 98K USD |
| Total Debt/Equity (mrq) | 0.07 USD |
| Current Ratio (mrq) | 34.939 |
| Book Value Per Share (mrq) | 3.792 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -40531000 USD |
| Levered Free Cash Flow (ttm) | -25210624 USD |
Profile of Cyteir Therapeutics
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 128 Spring Street |
| ZIP | 02421 |
| Phone | 857 285 4140 |
| Website | https://cyteir.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 46 |
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
Q&A For Cyteir Therapeutics Stock
What is a current CYT stock price?
Cyteir Therapeutics CYT stock price today per share is 3.02 USD.
How to purchase Cyteir Therapeutics stock?
You can buy CYT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cyteir Therapeutics?
The stock symbol or ticker of Cyteir Therapeutics is CYT.
Which industry does the Cyteir Therapeutics company belong to?
The Cyteir Therapeutics industry is Biotechnology.
How many shares does Cyteir Therapeutics have in circulation?
The max supply of Cyteir Therapeutics shares is 36M.
What is Cyteir Therapeutics Price to Earnings Ratio (PE Ratio)?
Cyteir Therapeutics PE Ratio is 0.00000000 now.
What was Cyteir Therapeutics earnings per share over the trailing 12 months (TTM)?
Cyteir Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Cyteir Therapeutics company belong to?
The Cyteir Therapeutics sector is Healthcare.
Cyteir Therapeutics CYT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16708.05 USD — |
+2.5
|
7.57B USD — | 16642.66 USD — | 17029.86 USD — | — - | 7.57B USD — |
| NYSE COMPOSITE (DJ) NYA | 18631.09 USD — |
+0.95
|
— — | — — | — — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4124.19 USD — |
+3.5
|
— — | 3927.42 USD — | 4124.19 USD — | — - | — — |
| PHLX Chemicals Index XCM | — — |
0
|
— — | — — | — — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8168.22 USD — |
+2.5
|
— — | 8135.98 USD — | 8324.83 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4116.15 USD — |
+1.68
|
— — | 4101.26 USD — | 4187.02 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 911.61 USD — |
+1.7
|
— — | 909.68 USD — | 929.8 USD — | — - | — — |
- {{ link.label }} {{link}}